Neurologix have provided details of a Phase 2 clinical trial of NLX-P101 in Parkinson's Disease. NLX-P101 is a gene therapy under investigation for the treatment of Parkinson's Disease. NLX-P101 increases the level of GABA, a substance involved in muscular movement that is naturally produced in the brain. In a one-year follow-up, patients treated with NLX-P101 who achieved clinically-meaningful symptom improvements increased from 50% at six months to 63% after one year. No serious adverse events related to the therapy or surgical procedure were reported.
NLX-P101 led to an average improvement of 23% in those people treated, which is an 8 point reduction from their symptom questionnaire score. Those patients undergoing sham surgery (those that were untreated) had an average improvement of nearly 13%, which is nearly a 5 point reduction from their symptom questionnaire score. Therefore the average improvement beyond that of doing nothing was only actually 10% and occurred in only just over half of patients.
